Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer
Open Access
- 5 August 2020
- Vol. 12 (8), 2193
- https://doi.org/10.3390/cancers12082193
Abstract
Biological heterogeneity and low inherent immunogenicity are two features that greatly impact therapeutic management and outcome in colorectal cancer. Despite high local control rates, systemic tumor dissemination remains the main cause of treatment failure and stresses the need for new developments in combined-modality approaches. While the role of adaptive immune responses in a small subgroup of colorectal tumors with inherent immunogenicity is indisputable, the challenge remains in identifying the optimal synergy between conventional treatment modalities and immune therapy for the majority of the less immunogenic cases. In this context, cytotoxic agents such as radiation and certain chemotherapeutics can be utilized to enhance the immunogenicity of an otherwise immunologically silent disease and enable responsiveness to immune therapy. In this review, we explore the immunological characteristics of colorectal cancer, the effects that standard-of-care treatments have on the immune system, and the opportunities arising from combining immune checkpoint-blocking therapy with immune-modulating conventional treatments.Funding Information
- Akershus Universitetssykehus (2017014, 2018002)
This publication has 151 references indexed in Scilit:
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaThe New England Journal of Medicine, 2012
- Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphomaBritish Journal of Cancer, 2011
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trialThe Lancet Oncology, 2010
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trialThe Lancet, 2008
- Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancerBritish Journal of Cancer, 2008
- T cell immune reconstitution following lymphodepletionSeminars in Immunology, 2007
- Elevated serum matrix metalloproteinase 9 (MMP-9) concentration predicts the presence of colorectal neoplasia in symptomatic patientsBritish Journal of Cancer, 2007
- Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesisProceedings of the National Academy of Sciences of the United States of America, 2006
- Cell death by mitotic catastrophe: a molecular definitionOncogene, 2004